Epidemiology of Kaposi's sarcoma in sub-Saharan Africa.

Acquired Immunodeficiency Syndrome / complications Africa South of the Sahara / epidemiology Female HIV Infections / epidemiology Herpesvirus 8, Human Humans Male Sarcoma, Kaposi / epidemiology Zimbabwe
Antiretroviral therapy Human immunodeficiency virus/acquired immunodeficiency syndrome Kaposi’s sarcoma Kaposi’s sarcoma-associated herpesvirus Sub-Saharan Africa

Journal

Cancer epidemiology
ISSN: 1877-783X
Titre abrégé: Cancer Epidemiol
Pays: Netherlands
ID NLM: 101508793

Informations de publication

Date de publication:
06 2022
Historique:
received: 09 12 2021
revised: 18 03 2022
accepted: 20 04 2022
pubmed: 4 5 2022
medline: 25 5 2022
entrez: 3 5 2022
Statut: ppublish

Résumé

Kaposi's sarcoma (KS) has become a common AIDS-defining cancer in sub-Saharan Africa. Kaposi's sarcoma-associated human herpesvirus strongly modulated by HIV-related immune suppression are the principal causes of this cancer. No other risk factors have been identified as playing a strong role. HIV prevention programs and good coverage of antiretroviral therapy (ART) in developed countries resulted in a remarkable decline in HIV-KS incidence and better KS prognosis. By contrast, in sub-Saharan Africa, population ART rollout has lagged, but clinical studies have shown positive results in reduction of KS incidence and better KS prognosis. However, the effect of ART rollout in relation to population KS incidence is unclear. We describe the incidence of KS in sub-Saharan Africa, in four time-periods, (1) before 1980 (before HIV/AIDS era); (2) 1981-2000 (early HIV/AIDS era, limited or no ART coverage); (3) 2001-2010 (early ART coverage period); and (4) 2011-2016 (fair to good ART coverage period). We used KS incidence data available from WHO-International Agency for Research on Cancer (IARC) publications and the Africa Cancer Registry Network. National HIV prevalence and ART coverage data were derived from UNAIDS/WHO. A rapid increase in KS incidence was observed throughout sub-Saharan Africa as the HIV epidemic progressed, reaching peak incidences in Period 2 (pre-ART rollout) of 50.8 in males and 20.3 per 100 000 in females (Zimbabwe, Harare). The overall unweighted average decline in KS incidence between 2000 and 2010 and 2011-2016 was 27%, but this decline was not statistically significant across the region. ART rollout coincides with a decline in KS incidence across several regions in sub-Saharan Africa. The importance of other risk factors such as reductions in HIV incidence could not be ascertained.

Identifiants

DOI: 10.1016/j.canep.2022.102167 PMID: 35504064
pubmed: 35504064
pii: S1877-7821(22)00072-8
doi: 10.1016/j.canep.2022.102167
pii:
doi:

Types de publication

Journal Article Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

102167

Subventions

Organisme : Medical Research Council
ID : MRC-RFA-SHIP 01-2015
Pays : United Kingdom

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.

Auteurs

Melitah Motlhale (M)

National Cancer Registry, National Health Laboratory Service, Johannesburg, South Africa; Division of Epidemiology and Biostatistics, School of Public Health, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa. Electronic address: melitahm@nicd.ac.za.

Freddy Sitas (F)

Burden of Disease Research Unit, South African Medical Research Council, Cape Town, South Africa; Centre for Primary Health Care and Equity, School of Population Health, University of New South Wales Sydney, Australia; Menzies Centre of Health Policy, School of Public Health, University of Sydney, Australia.

Debbie Bradshaw (D)

Burden of Disease Research Unit, South African Medical Research Council, Cape Town, South Africa.

Wenlong Carl Chen (WC)

National Cancer Registry, National Health Laboratory Service, Johannesburg, South Africa; Sydney Brenner Institute for Molecular Bioscience, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.

Mwiza Gideon Singini (MG)

National Cancer Registry, National Health Laboratory Service, Johannesburg, South Africa; Division of Epidemiology and Biostatistics, School of Public Health, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa.

Chantal Babb de Villiers (CB)

Division of Human Genetics, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.

Cathryn M Lewis (CM)

Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology & Neuroscience, King's College London, SE5 8AF, United Kingdom; Department of Medical and Molecular Genetics, Faculty of Life Sciences and Medicine, King's College London, SE1 9RT, United Kingdom.

Mazvita Muchengeti (M)

National Cancer Registry, National Health Laboratory Service, Johannesburg, South Africa; Division of Epidemiology and Biostatistics, School of Public Health, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa; South African DSI-NRF Centre of Excellence in Epidemiological Modelling and Analysis (SACEMA), Stellenbosch University, Stellenbosch, South Africa.

Tim Waterboer (T)

Division of Infections and Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Christopher G Mathew (CG)

Sydney Brenner Institute for Molecular Bioscience, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; Division of Human Genetics, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; Department of Medical and Molecular Genetics, Faculty of Life Sciences and Medicine, King's College London, SE1 9RT, United Kingdom.

Robert Newton (R)

MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda; University of York, York, United Kingdom.

Elvira Singh (E)

National Cancer Registry, National Health Laboratory Service, Johannesburg, South Africa; Division of Epidemiology and Biostatistics, School of Public Health, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Maladies du système immunitaire › Déficits immunitaires › Infections à VIH › Syndrome d'immunodéficience acquise › Epidemiology of Kaposi's sarcoma in sub-Saharan Africa.
questionsmedicales.fr › Régions géographiques › Afrique › Afrique subsaharienne › Epidemiology of Kaposi's sarcoma in sub-Saharan Africa.
questionsmedicales.fr › Maladies du système immunitaire › Déficits immunitaires › Infections à VIH › Epidemiology of Kaposi's sarcoma in sub-Saharan Africa.
questionsmedicales.fr › Virus › Virus oncogènes › Virus tumoraux à ADN › Gammaherpesvirinae › Rhadinovirus › Herpèsvirus humain de type 8 › Epidemiology of Kaposi's sarcoma in sub-Saharan Africa.
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Epidemiology of Kaposi's sarcoma in sub-Saharan Africa.
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Tumeurs du tissu vasculaire › Sarcome de Kaposi › Epidemiology of Kaposi's sarcoma in sub-Saharan Africa.
questionsmedicales.fr › Régions géographiques › Afrique › Afrique subsaharienne › Afrique australe › Zimbabwe › Epidemiology of Kaposi's sarcoma in sub-Saharan Africa.